Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Kevesy

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Levetiracetam Testmiljö

Levetiracetam

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Keppra (levetiracetam). Summary of Product Characteristics. Swedish Medical Products Agency (MPA) [updated 2019-03-01, cited 2019-10-09].

  2. Keppra (levetiracetam). DailyMed [www]. US National Library of Medicine. [updated 2017-11-07, cited 2019-10-09].

  3. US Food and Drug Administration. Statistical Review(s) - KEPPRA (levetiracetam). Drugs@FDA [www]. [updated 2001-08-30, cited 2019-10-09].

  4. US Food and Drug Administration. Clinical Pharmacology Biopharmaceutics Review - KEPPRA (levetiracetam). Drugs@FDA [www]. [updated 2001-08-30, cited 2019-10-09].

  5. Alzueta, N, Ortega, A, and Aldaz, A. Influence of Sex, Age, and Weight on Levetiracetam Pharmacokinetics. Ther Drug Monit. 2018;40(5):628-634.

  6. Glauser TA, Mitchell WG, Weinstock A, Bebin M, Chen D, Coupez R et al. Pharmacokinetics of levetiracetam in infants and young children with epilepsy. Epilepsia. 2007;48:1117-22.

  7. Artemiadis AK, Lambrinoudaki I, Voskou P, Tsivgoulis G, Safouris A, Bougea A et al. Preliminary evidence for gender effects of levetiracetam monotherapy duration on bone health of patients with epilepsy. Epilepsy Behav. 2016;55:84-6.

  8. Svalheim S, Taubøll E, Luef G, Lossius A, Rauchenzauner M, Sandvand F et al. Differential effects of levetiracetam, carbamazepine, and lamotrigine on reproductive endocrine function in adults. Epilepsy Behav. 2009;16:281-7.

  9. Rauchenzauner M, Bitsche G, Svalheim S, Tauboll E, Haberlandt E, Wildt L et al. Effects of levetiracetam and valproic acid monotherapy on sex-steroid hormones in prepubertal children--results from a pilot study. Epilepsy Res. 2010;88:264-8.

  10. Wu D, Chen L, Ji F, Si Y, Sun H. The effects of oxcarbazepine, levetiracetam, and lamotrigine on semen quality, sexual function, and sex hormones in male adults with epilepsy. Epilepsia. 2018;59(7):1344-1350.

  11. Yogarajah M, Mula M. Sexual Dysfunction in Epilepsy and the Role of Anti-Epileptic Drugs. Curr Pharm Des. 2017;23(37):5649-5661.

  12. Ceylan M , Yalcin A, Bayraktutan OF , Karabulut I, Sonkaya AR. Effects of levetiracetam monotherapy on sperm parameters and sex hormones: Data from newly diagnosed patients with epilepsy. Epilepsia. 2016;41:70-4.

  13. Tomson T, Landmark CJ, Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia. 2013;54:405-14.

  14. Mintzer S, Trinka E, Kraemer G, Chervoneva I, Werhahn KJ. Impact of carbamazepine, lamotrigine, and levetiracetam on vascular risk markers and lipid-lowering agents in the elderly. Epilepsia. 2018;59(10):1899-1907.

  15. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]

  1. Keppra (levetiracetam). Summary of Product Characteristics. Swedish Medical Products Agency (MPA) [updated 2019-03-01, cited 2019-10-09].
  2. Keppra (levetiracetam). DailyMed [www]. US National Library of Medicine. [updated 2017-11-07, cited 2019-10-09].
  3. US Food and Drug Administration. Statistical Review(s) - KEPPRA (levetiracetam). Drugs@FDA [www]. [updated 2001-08-30, cited 2019-10-09].
  4. US Food and Drug Administration. Clinical Pharmacology Biopharmaceutics Review - KEPPRA (levetiracetam). Drugs@FDA [www]. [updated 2001-08-30, cited 2019-10-09].
  5. Alzueta, N, Ortega, A, and Aldaz, A. Influence of Sex, Age, and Weight on Levetiracetam Pharmacokinetics. Ther Drug Monit. 2018;40(5):628-634.
  6. Glauser TA, Mitchell WG, Weinstock A, Bebin M, Chen D, Coupez R et al. Pharmacokinetics of levetiracetam in infants and young children with epilepsy. Epilepsia. 2007;48:1117-22.
  7. Artemiadis AK, Lambrinoudaki I, Voskou P, Tsivgoulis G, Safouris A, Bougea A et al. Preliminary evidence for gender effects of levetiracetam monotherapy duration on bone health of patients with epilepsy. Epilepsy Behav. 2016;55:84-6.
  8. Svalheim S, Taubøll E, Luef G, Lossius A, Rauchenzauner M, Sandvand F et al. Differential effects of levetiracetam, carbamazepine, and lamotrigine on reproductive endocrine function in adults. Epilepsy Behav. 2009;16:281-7.
  9. Rauchenzauner M, Bitsche G, Svalheim S, Tauboll E, Haberlandt E, Wildt L et al. Effects of levetiracetam and valproic acid monotherapy on sex-steroid hormones in prepubertal children--results from a pilot study. Epilepsy Res. 2010;88:264-8.
  10. Wu D, Chen L, Ji F, Si Y, Sun H. The effects of oxcarbazepine, levetiracetam, and lamotrigine on semen quality, sexual function, and sex hormones in male adults with epilepsy. Epilepsia. 2018;59(7):1344-1350.
  11. Yogarajah M, Mula M. Sexual Dysfunction in Epilepsy and the Role of Anti-Epileptic Drugs. Curr Pharm Des. 2017;23(37):5649-5661.
  12. Ceylan M , Yalcin A, Bayraktutan OF , Karabulut I, Sonkaya AR. Effects of levetiracetam monotherapy on sperm parameters and sex hormones: Data from newly diagnosed patients with epilepsy. Epilepsia. 2016;41:70-4.
  13. Tomson T, Landmark CJ, Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia. 2013;54:405-14.
  14. Mintzer S, Trinka E, Kraemer G, Chervoneva I, Werhahn KJ. Impact of carbamazepine, lamotrigine, and levetiracetam on vascular risk markers and lipid-lowering agents in the elderly. Epilepsia. 2018;59(10):1899-1907.
  15. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]